Elanco Animal Health Incorporated Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Elanco Animal Health Incorporated Common Stock trades at $22.55 (market cap $11.20B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Elanco Animal Health Incorporated Common Stock and Vaxcyte Inc. Common Stock are close in size by market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Elanco Animal Health Incorporated Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elanco Animal Health Incorporated Common Stock for 6 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| ELAN | PCVX | |
|---|---|---|
Market Cap | $11.20B | $10.51B |
Volume | 3,345,224 | 2,644,694 |
Sector | Health | Health |
52-Week High | $26.84 | $73.82 |
52-Week Low | $19.80 | $40.32 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $14.58B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
ELAN trades at $22.41, down 0.66% today, with a bearish technical signal from moving averages. The company reported a net loss of $232 million in 2025, though revenue grew to $4.72 billion. Recent earnings beats and a 71% analyst buy rating reflect optimism around new product launches like Zenrelia and deleveraging plans discussed at recent conferences.
The outlook hinges on execution of growth initiatives to achieve profitability. Upside exists if new products gain market share as projected, but risks include persistent losses, competitive pressures, and high debt. The consensus price target of $28.00 suggests 25% potential upside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Elanco develops medicines, vaccines, and other health products for pets and livestock. Its products address prevention and treatment of animal diseases.
Read more on ELAN →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →